The past 20 years has seen transdermal technology become an accepted method of delivering medicines as they can offer significant clinical benefits over other dosage forms.
The Food and Drug Administration (FDA) approved the first transdermal patch in 1979 for the treatment of motion sickness, since then it has approved more than 35 transdermal products containing more 13 molecules.
Syntropharma have identified numerous molecules which can be successfully delivered through the skin at therapeutically relevant levels since they began in 2006.
They have assembled a team of experts who have many years’ experience developing transdermal products. They employ rigorous criteria to the selection of suitable drug development candidates; mindful of the market need for improved, well differentiated and protected medicines.